Cellyan Biotechnology (HKPD) Receivables - Net (2024 - 2025)
Cellyan Biotechnology's (HKPD) quarterly Receivables - Net came in at $5.1 million in Q3 2025, up 4.36% year-on-year from $4.9 million in Q3 2024, and up 9.39% on a QoQ basis from $4.7 million in Q1 2025.
Cellyan Biotechnology (HKPD) Receivables - Net (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Receivables - Net data on file, last reported at $5.1 million in Q3 2025.
- On a quarterly basis, Receivables - Net rose 4.36% year-over-year to $5.1 million in Q3 2025; TTM through Sep 2025 was $5.1 million, a 4.36% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 25.88% from the prior year.
- Receivables - Net for Q3 2025 stood at $5.1 million, up from $4.7 million in the prior quarter.
- Over the last five years, Receivables - Net for HKPD reached as high as $5.1 million in Q3 2025 and fell as low as $3.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Mckesson | 105.15 Bn | 101.18 Bn | 4.04 Bn |
| 2 | Cencora | 60.58 Bn | 58.40 Bn | 3.59 Bn |
| 3 | Cardinal Health | 53.81 Bn | 49.87 Bn | 2.50 Bn |
| 4 | Henry Schein | 9.71 Bn | 9.57 Bn | 1.07 Bn |
| 5 | Akso Health | 3.28 Bn | 3.28 Bn | - |
| 6 | 111 | 651.73 Mn | 572.63 Mn | 23.58 Mn |
| 7 | Accendra Health | 248.02 Mn | -88.86 Mn | 278.03 Mn |
| 8 | Edap Tms | 230.14 Mn | 215.14 Mn | 8.15 Mn |
| 9 | VitaNova Life Sciences | 11.51 Mn | 11.01 Mn | 316,343.00 |
| 10 | Cellyan Biotechnology | 4.19 Mn | 3.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.09 Mn |
| Sep 30, 2025 | 5.09 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Mar 31, 2024 | 3.70 Mn |